Status:
TERMINATED
Infant Formula and Toddler Drink Feeding Intervention
Lead Sponsor:
Abbott Nutrition
Conditions:
Respiratory Infections in Children
Eligibility:
All Genders
Up to 14 years
Phase:
NA
Brief Summary
The purpose of this randomized, multi-center, controlled, double-blind, parallel study is to evaluate the health and developmental outcomes of children fed a new infant formula and toddler drink throu...
Eligibility Criteria
Inclusion
- Participant is judged to be in good health as determined from participant's medical history
- Participant is a singleton from a full-term birth with a gestational age of 37 - 42 weeks
- Participant's birth weight was ≥ 2490 g (\~5 lbs. 8 oz.)
- If parent(s) elect to formula feed the participant they confirm their intention to feed their participant the study product as the sole source of feeding until 4 months of age, and as the sole milk beverage during the first 12 months of life
- If parent(s) elect to formula feed the participant, they confirm their intention to feed the participant the assigned toddler drink from 12 months of life to 24 months of life as the primary milk beverage
- If parent(s) elect to feed the participant mother's human milk, they confirm that their infant was exclusively fed mother's human milk since birth and confirm their intention to continue exclusively feeding human milk as the sole source of feeding through 4 months of age
- If parent(s) of human milk fed participant elect to supplement or wean after 4 months to 24 months of age, they confirm their intention to use the supplemental/weaning formula or toddler drink as the primary milk beverage
- Parent(s) of formula-fed participant confirm their intention not to administer vitamin or mineral supplements, from enrollment through the duration of the study
- Parent(s) confirm their intention not to administer solid foods or juices to the participant from enrollment through 6 months of age
- Participant's parent(s) has voluntarily signed and dated an informed consent form (ICF), approved by an Institutional Review Board/Independent Ethics Committee (IRB/IEC) and provided Health Insurance Portability and Accountability Act (HIPAA) (or other applicable privacy regulation) authorization prior to any participation in the study.
Exclusion
- An adverse maternal, fetal or participant medical history that is thought by the investigator to have potential for effects on tolerance, growth, and/or development
- Participant is taking and plans to continue medications (including over the counter (OTC), home remedies, herbal preparations, prebiotics or probiotics, or rehydration fluids that might affect GI tolerance
- Participant is in another study that has not been approved as a concomitant study
- Participant has been treated with antibiotics prior to enrollment
Key Trial Info
Start Date :
August 10 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 12 2021
Estimated Enrollment :
168 Patients enrolled
Trial Details
Trial ID
NCT04495738
Start Date
August 10 2020
End Date
April 12 2021
Last Update
May 14 2021
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
Southeastern Pediatric Associates
Dothan, Alabama, United States, 36305
2
Eclipse Clinical Research
Tucson, Arizona, United States, 85745
3
The Children's Clinic of Jonesboro, P.A.
Jonesboro, Arkansas, United States, 72401
4
Applied Research Center of Arkansas
Little Rock, Arkansas, United States, 72019